Conexeu Sciences to Present at Key Biotech Conferences Amid…

Event summary

Conexeu Sciences will present at three investor conferences in September and October 2026, including Nasdaq/LD Micro Summit Series and H.C. Wainwright's Global Investment Conference.
CEO Miles Harrison and Chief Medical Officer Brian Pilcher will lead presentations and one-on-one meetings with investors.
The company is preparing for a 510(k) submission in early 2027 for its lead device candidate, Ten-Minute Tissue™, targeting wound care and tissue restoration markets.
Conexeu's CXU™ platform is protected by patents in over 40 jurisdictions with no royalty or licensing obligations.

The big picture

Conexeu Sciences is positioning itself for a critical regulatory milestone with its upcoming 510(k) submission, while actively engaging with investors to support its expansion into multi-billion-dollar markets. The company's patent-protected platform and strategic conference appearances reflect its push to establish itself in the competitive regenerative medicine space. Success will depend on navigating regulatory hurdles and securing sufficient capital to advance its preclinical pipeline.

What we're watching

Regulatory Timeline: Whether Conexeu can maintain its target 510(k) submission timeline amid potential FDA scrutiny or additional data requirements.
Market Expansion: The pace at which Conexeu can scale its CXU platform across multiple indications, including wound care and tissue restoration.
Investor Sentiment: How investor interest at these conferences translates into potential partnerships or funding for Conexeu's preclinical-stage platform.